SG11201503684WA - Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors - Google Patents
Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressorsInfo
- Publication number
- SG11201503684WA SG11201503684WA SG11201503684WA SG11201503684WA SG11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA SG 11201503684W A SG11201503684W A SG 11201503684WA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrimido
- diones
- quinoline
- nonsense mutation
- mutation suppressors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Inorganic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736748P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/060859 WO2014091446A1 (en) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503684WA true SG11201503684WA (en) | 2015-06-29 |
Family
ID=50030361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503684WA SG11201503684WA (en) | 2012-12-13 | 2013-12-12 | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9649314B2 (de) |
| EP (1) | EP2931282B1 (de) |
| JP (1) | JP6076498B2 (de) |
| KR (1) | KR101760586B1 (de) |
| CN (2) | CN104837490B (de) |
| AP (1) | AP2015008441A0 (de) |
| AU (1) | AU2013358591B2 (de) |
| BR (1) | BR112015013535A2 (de) |
| CA (1) | CA2890692A1 (de) |
| CL (1) | CL2015001610A1 (de) |
| CR (1) | CR20150314A (de) |
| CU (1) | CU20150061A7 (de) |
| EA (1) | EA028673B1 (de) |
| ES (1) | ES2709034T3 (de) |
| HK (1) | HK1209637A1 (de) |
| IL (1) | IL239244A0 (de) |
| IN (1) | IN2015DN03998A (de) |
| MA (1) | MA38157A1 (de) |
| MX (1) | MX363437B (de) |
| PE (1) | PE20151062A1 (de) |
| PH (1) | PH12015501216A1 (de) |
| SG (1) | SG11201503684WA (de) |
| TN (1) | TN2015000262A1 (de) |
| WO (1) | WO2014091446A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015DN03998A (de) | 2012-12-13 | 2015-10-02 | Novartis Ag | |
| JP6560257B2 (ja) * | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体 |
| CA2950724A1 (en) * | 2014-06-03 | 2015-12-10 | Novartis Ag | Naphthyridinedione derivatives |
| JP6526064B2 (ja) * | 2014-06-03 | 2019-06-05 | ノバルティス アーゲー | ピリドピリミジンジオン誘導体 |
| EP3442512A4 (de) * | 2016-04-15 | 2020-07-22 | The UAB Research Foundation | Verfahren und verbindungen zur stimulierung des durchlesens von codons mit vorzeitiger terminierung |
| WO2019173437A1 (en) * | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Positive allosteric modulators of dopamine 1 receptor and method of use thereof |
| WO2019225625A1 (ja) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) * | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| US5908930A (en) | 1995-03-15 | 1999-06-01 | Pfizer Inc. | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| KR101134188B1 (ko) | 2003-04-11 | 2012-04-12 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산 화합물 |
| ES2594343T3 (es) | 2006-04-03 | 2016-12-19 | Technion Research & Development Foundation Limited | Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos |
| CA2660951A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| EP2219646A4 (de) * | 2007-12-21 | 2010-12-22 | Univ Rochester | Verfahren zur verlängerung der lebensdauer eukaryotischer organismen |
| EP2422817A1 (de) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-Nukleinsäureligandenkonjugate |
| CN103189060A (zh) | 2010-08-05 | 2013-07-03 | 里尔法律与医疗卫生第二大学 | 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物 |
| IN2015DN03998A (de) | 2012-12-13 | 2015-10-02 | Novartis Ag |
-
2013
- 2013-12-12 IN IN3998DEN2015 patent/IN2015DN03998A/en unknown
- 2013-12-12 KR KR1020157018231A patent/KR101760586B1/ko active IP Right Grant
- 2013-12-12 CN CN201380064035.5A patent/CN104837490B/zh not_active Expired - Fee Related
- 2013-12-12 CA CA2890692A patent/CA2890692A1/en not_active Abandoned
- 2013-12-12 CN CN201710826258.0A patent/CN107569487A/zh active Pending
- 2013-12-12 SG SG11201503684WA patent/SG11201503684WA/en unknown
- 2013-12-12 ES ES13826612T patent/ES2709034T3/es active Active
- 2013-12-12 US US14/652,102 patent/US9649314B2/en not_active Expired - Fee Related
- 2013-12-12 AU AU2013358591A patent/AU2013358591B2/en not_active Ceased
- 2013-12-12 WO PCT/IB2013/060859 patent/WO2014091446A1/en active Application Filing
- 2013-12-12 BR BR112015013535A patent/BR112015013535A2/pt not_active Application Discontinuation
- 2013-12-12 MX MX2015007562A patent/MX363437B/es unknown
- 2013-12-12 JP JP2015547244A patent/JP6076498B2/ja not_active Expired - Fee Related
- 2013-12-12 AP AP2015008441A patent/AP2015008441A0/xx unknown
- 2013-12-12 EP EP13826612.7A patent/EP2931282B1/de active Active
- 2013-12-12 PE PE2015000911A patent/PE20151062A1/es not_active Application Discontinuation
- 2013-12-12 EA EA201591105A patent/EA028673B1/ru not_active IP Right Cessation
-
2015
- 2015-05-29 PH PH12015501216A patent/PH12015501216A1/en unknown
- 2015-06-04 IL IL239244A patent/IL239244A0/en unknown
- 2015-06-05 MA MA38157A patent/MA38157A1/fr unknown
- 2015-06-09 TN TNP2015000262A patent/TN2015000262A1/fr unknown
- 2015-06-10 CL CL2015001610A patent/CL2015001610A1/es unknown
- 2015-06-12 CR CR20150314A patent/CR20150314A/es unknown
- 2015-06-12 CU CUP2015000061A patent/CU20150061A7/es unknown
- 2015-10-23 HK HK15110447.1A patent/HK1209637A1/xx unknown
-
2017
- 2017-04-04 US US15/478,778 patent/US20170266189A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239244A0 (en) | Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations | |
| HRP20181349T1 (hr) | Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina | |
| HRP20171724T1 (hr) | Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze | |
| HK1246792A1 (zh) | 6，7-二氫吡唑並[1，5-a]吡嗪-4(5h)-酮化合物 | |
| HK1219277A1 (zh) | 新的三唑並 嘧啶衍生物 | |
| HK1206014A1 (en) | Pyrazolo triazine derivatives as selective cyclin dependent kinase inhinitors | |
| HK1210167A1 (en) | Macrocycle picolinamides as fungicides -2- | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2945632A4 (de) | Heterobcyclosubstituierte [1,2,4]triazolo[1,5-c]chinazolin-5-amin-verbindungen mit a2a-antagonistischen eigenschaften | |
| HK1199879A1 (en) | Pde9 inhibitors with imidazo triazinone backbone pde9 | |
| EP2968311A4 (de) | Oxazolo[5,4-c]chinolin-2-on-verbindungen als bromdomänenhemmer | |
| ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| PL3129374T3 (pl) | (5,6-Dihydro)pirymido[4,5-e]indolizyny | |
| HK1187614A1 (zh) | 咪唑並吡嗪 | |
| EP2925876A4 (de) | Fräsverfahren | |
| HK1206354A1 (en) | Pyrrolo[2,3-b]pyrazines as syk inhibitors syk [23-b] | |
| HK1220196A1 (zh) | 抗病毒吲哚並 喹喔啉 | |
| EP2925790A4 (de) | Fräsverfahren | |
| HK1209419A1 (en) | Solid form of dihydro pyrido oxazine derivative | |
| IL236808B (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| GB201211756D0 (en) | Novel isothiazolo [4,3-b]pyridines | |
| GB201219129D0 (en) | Triazolo(4,5-d)pyrmindine compounds |